Halogen-stabilized insulin
US8921313B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 31, 2011 |
| Grant date | Dec 30, 2014 |
| Priority date | — |
| Expiry date | Jan 31, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.